- Home
- HIFS vs CAPR Comparison
HIFS vs CAPR Comparison
Compare HIFS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- CAPR
- Stock Information
- Founded
- HIFS 1834
- CAPR 2005
- Country
- HIFS United States
- CAPR United States
- Employees
- HIFS N/A
- CAPR N/A
- Industry
- HIFS Major Banks
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HIFS Finance
- CAPR Health Care
- Exchange
- HIFS Nasdaq
- CAPR Nasdaq
- Market Cap
- HIFS 518.9M
- CAPR 578.4M
- IPO Year
- HIFS N/A
- CAPR N/A
- Fundamental
- Price
- HIFS $260.96
- CAPR $15.00
- Analyst Decision
- HIFS
- CAPR Strong Buy
- Analyst Count
- HIFS 0
- CAPR 7
- Target Price
- HIFS N/A
- CAPR $39.29
- AVG Volume (30 Days)
- HIFS 12.7K
- CAPR 902.1K
- Earning Date
- HIFS 04-11-2025
- CAPR 03-03-2025
- Dividend Yield
- HIFS 0.97%
- CAPR N/A
- EPS Growth
- HIFS 6.91
- CAPR N/A
- EPS
- HIFS 12.85
- CAPR N/A
- Revenue
- HIFS $65,525,000.00
- CAPR $23,228,045.00
- Revenue This Year
- HIFS N/A
- CAPR N/A
- Revenue Next Year
- HIFS N/A
- CAPR $74.85
- P/E Ratio
- HIFS $20.31
- CAPR N/A
- Revenue Growth
- HIFS 3.21
- CAPR 65.33
- 52 Week Low
- HIFS $160.00
- CAPR $3.52
- 52 Week High
- HIFS $300.00
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- HIFS 47.82
- CAPR 52.56
- Support Level
- HIFS $267.70
- CAPR $14.28
- Resistance Level
- HIFS $281.61
- CAPR $16.47
- Average True Range (ATR)
- HIFS 8.51
- CAPR 1.00
- MACD
- HIFS 0.17
- CAPR 0.07
- Stochastic Oscillator
- HIFS 48.31
- CAPR 55.05
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.